GeneReach Competitors

Stocks . Taiwan . 
Stock . GeneReach Biotechnology
4171 Stock  TWD 28.90  0.20  0.70%   
GeneReach Biotechnology competes with Acelon Chemicals, Shinkong Synthetic, Fortune Information, Evergreen International, and Shiny Chemical; as well as few others. The company operates under Healthcare sector and is part of Biotechnology industry. Analyzing GeneReach Biotechnology competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of GeneReach Biotechnology to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out GeneReach Biotechnology Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of GeneReach Biotechnology competition on your existing holdings.
  
Hype
Prediction
LowEstimatedHigh
27.7528.9030.05
Details
Intrinsic
Valuation
LowRealHigh
22.5523.7031.79
Details
Naive
Forecast
LowNextHigh
27.1228.2729.42
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
28.4328.7729.11
Details

GeneReach Biotechnology Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between GeneReach Biotechnology and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of GeneReach and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of GeneReach Biotechnology does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
3570
+ 0.5
1466
6697
+ 0.48
2607
2607
+ 0.42
1466
3260
+ 0.42
1409
6697
+ 0.38
1466
1773
+ 0.35
1409
  
High negative correlations   
3570
- 0.6
1773
3570
- 0.6
2468
6697
- 0.47
1409
2468
- 0.39
1466
3570
- 0.26
1409
1409
- 0.23
1466

Risk-Adjusted Indicators

There is a big difference between GeneReach Stock performing well and GeneReach Biotechnology Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze GeneReach Biotechnology's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
All Fundamental Data

GeneReach Biotechnology Competitive Analysis

The better you understand GeneReach Biotechnology competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, GeneReach Biotechnology's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across GeneReach Biotechnology's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
4171 1466 1409 2468 2607 1773 6697 3570 3260
 0.70 
 28.90 
GeneReach
 0.72 
 13.95 
Acelon
 0.94 
 16.05 
Shinkong
 1.61 
 21.45 
Fortune
 0.81 
 31.00 
Evergreen
 0.61 
 166.00 
Shiny
 1.87 
 44.60 
Information
 1.46 
 169.00 
Otsuka
 0.34 
 87.20 
Adata
Market Volatility
(90 Days Market Risk)
Very steady
Not too volatile
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Market Performance
(90 Days Performance)
Very Weak
Modest
Very Weak
Very Weak
Weak
Weak
Very Weak
Modest
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
Below Average
Below Average
Low
Low
Low
Low
Low
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Fairly Valued
Under Valued
Over Valued
Fairly Valued
Fairly Valued
Over Valued
Fairly Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Hold
Hold
Strong Hold
Strong Hold
Hold
Strong Hold
Strong Hold
Hold
Buy
Current Ratio
5.21
1.42
0.91
2.73
2.07
0.99
N/A
4.07
1.54
Net Asset
1.68 B
3.68 B
196.03 B
1.86 B
41.81 B
10.94 B
N/A
N/A
32.8 B
Profit Margin
0.38
0.0126
0.0779
0.0268
0.19
0.16
N/A
N/A
0.0187
EBITDA
535.64 M
420.56 M
8.35 B
72.57 M
3.46 B
2.33 B
N/A
135.66 M
3.8 B
Operating Margin
0.43
-0.0054
0.13
0.0254
0.18
0.18
N/A
N/A
0.028
Current Valuation
2.09 B
2.47 B
52.93 B
2.01 B
28.72 B
31.99 B
N/A
N/A
28.81 B
Price To Book
2.37
0.79
0.82
1.68
1.01
3.8
N/A
N/A
1.33
Retained Earnings
N/A
208 M
6.39 B
362 M
5.36 B
2.3 B
N/A
N/A
N/A
Current Asset
N/A
1.53 B
77.59 B
987 M
4.92 B
2.47 B
N/A
N/A
N/A
Five Year Return
N/A
N/A
3.47
3.9
2.4
3.79
N/A
5.06
4.45
Beta
0.63
0.53
0.71
0.55
0.75
0.72
N/A
0.84
1.59
Number Of Employees
16
10
29
19
34
15
N/A
10
24
Shares Outstanding
45.97 M
111.16 M
1.61 B
69.96 M
1.07 B
250 M
N/A
N/A
263.46 M
Cash Flow From Operations
348.99 M
167.28 M
(2.56 B)
185.65 M
2.9 B
1.42 B
N/A
83.15 M
(1.19 B)
Annual Yield
0.0835
0.0858
0.0776
0.0135
0.0144
0.0231
N/A
N/A
0.0828
Total Debt
217.39 M
641.76 M
15.79 B
19.16 M
5.5 B
1.1 B
N/A
39.73 M
4.84 B
Return On Equity
0.3
0.023
0.1
0.0506
0.12
0.26
N/A
N/A
0.0623
Z Score
7.2
1.2
0.6
63.4
3.0
19.0
N/A
23.4
2.8
Return On Asset
0.13
-0.0028
0.021
0.0175
0.0483
0.12
N/A
N/A
0.019
Book Value Per Share
24.36
14.87
21.54
16.8
27.49
30.69
N/A
36.06
44.37
Current Liabilities
N/A
1.34 B
84.56 B
367 M
2.1 B
1.1 B
N/A
N/A
N/A
Total Asset
1.68 B
3.68 B
196.03 B
1.86 B
41.81 B
10.94 B
N/A
N/A
32.8 B
Debt To Equity
0.3
77.7
88.5
1.6
34.2
0.38
N/A
6.4
1.31
Last Dividend Paid
4.55
1.0
1.4
0.4
0.4
2.4
N/A
3.0
5.5
Target Price
N/A
32.5
N/A
N/A
18.6
50.0
N/A
N/A
117.0
Shares Owned By Institutions
4.57
N/A
12.7
N/A
4.8
2.89
N/A
N/A
7.22
Market Capitalization
2.73 B
1.29 B
28.89 B
2.01 B
29.13 B
33 B
N/A
1.55 B
17.86 B
Price To Earning
8.39
-11.91
8.38
18.92
17.41
14.21
N/A
15.16
13.2
Price To Sales
2.88
0.43
0.59
0.87
1.74
2.48
N/A
N/A
0.42
Net Income
376.62 M
177.88 M
3.89 B
44.68 M
1.06 B
1.62 B
N/A
102.98 M
2.25 B
Earnings Per Share
6.9
0.35
2.27
0.84
3.13
7.37
N/A
5.97
2.61
Shares Owned By Insiders
34.96
41.88
30.46
72.52
59.6
60.17
N/A
N/A
8.92
Revenue
1.01 B
3.57 B
44.16 B
2.15 B
8.88 B
11.14 B
N/A
N/A
39.59 B
Working Capital
N/A
196 M
(6.98 B)
620 M
2.82 B
1.37 B
N/A
N/A
N/A
Cash And Equivalents
811.4 M
39.08 M
13.41 B
273.16 M
5.09 B
286.24 M
N/A
377.57 M
2.98 B
Cash Per Share
17.65
0.35
8.32
3.9
4.77
1.14
N/A
22.08
12.26
Gross Profit
746.98 M
621.36 M
12.06 B
231.96 M
1.35 B
3.13 B
N/A
N/A
5.77 B
Day Typical Price
28.82
13.95
15.98
21.42
30.83
165.33
44.83
168.33
87.13
Accumulation Distribution
0.0087
0.049
0.0125
0.0093
0.0161
0.024
0.0328
0.0177
0.0159
Market Facilitation Index
0.25
0.7
0.2
0.2
0.5
4.0
1.5
3.0
1.4
Daily Balance Of Power
0.8
0.1429
0.75
(1.75)
0.5
0.25
(0.57)
(0.83)
(0.21)
Period Momentum Indicator
0.2
0.1
0.15
(0.35)
0.25
1.0
(0.85)
(2.50)
(0.30)
Rate Of Daily Change
1.01
1.01
1.01
0.98
1.01
1.01
0.98
0.99
1.0
Day Median Price
28.78
13.95
15.95
21.4
30.75
165.0
44.95
168.0
87.1
Price Action Indicator
0.22
0.05
0.18
(0.13)
0.38
1.5
(0.78)
(0.25)
(0.05)
Relative Strength Index
45.09
74.27
37.14
32.51
42.0
42.94
58.64
84.23
57.05
Coefficient Of Variation
(1,374)
1425.33
17774.99
(1,263)
19018.08
3119.24
8606.95
1492.24
(960.18)
Mean Deviation
1.04
2.05
0.8181
1.43
0.7487
1.68
1.23
1.28
0.8273
Jensen Alpha
(0.15)
0.0158
(0.03)
(0.21)
(0)
(0.03)
(0.03)
0.0897
(0.18)
Total Risk Alpha
(0.42)
(0.30)
(0.19)
(0.52)
(0.18)
(0.30)
(0.33)
(0.21)
(0.33)
Sortino Ratio
N/A
0.0299
(0.11)
N/A
(0.10)
(0.03)
(0.06)
(0.0006)
N/A
Downside Variance
N/A
5.73
1.56
N/A
1.64
4.93
3.93
3.35
N/A
Standard Deviation
1.73
2.98
1.14
2.08
1.06
2.16
2.06
2.04
1.18
Kurtosis
17.51
2.62
1.9
4.07
2.45
0.1098
8.37
7.25
1.91
Potential Upside
1.43
5.81
1.63
3.25
1.64
3.81
2.33
3.67
1.46
Treynor Ratio
(1.63)
0.1386
(0.02)
(0.71)
1.05
0.0842
0.042
0.4385
(0.37)
Maximum Drawdown
14.48
14.96
5.02
11.17
5.44
9.34
15.29
13.46
6.27
Variance
2.98
8.89
1.29
4.32
1.13
4.68
4.23
4.15
1.39
Market Risk Adjusted Performance
(1.62)
0.1486
(0.01)
(0.70)
1.06
0.0942
0.052
0.4485
(0.36)
Risk Adjusted Performance
(0.05)
0.0611
0.0076
(0.05)
0.0068
0.031
0.0152
0.0575
(0.08)
Skewness
2.71
1.24
(0.56)
0.7085
(0.80)
0.1054
1.36
1.64
(0.16)
Semi Deviation
N/A
1.97
1.07
N/A
1.1
1.97
1.69
1.4
N/A
Information Ratio
(0.15)
0.024
(0.12)
(0.15)
(0.12)
(0.03)
(0.06)
(0.0005)
(0.22)
Value At Risk
(2.38)
(4.03)
(1.86)
(2.61)
(1.75)
(3.53)
(2.68)
(3.09)
(2.10)
Expected Short fall
N/A
(3.14)
(1.04)
N/A
(0.83)
(1.92)
(1.53)
(1.82)
N/A
Downside Deviation
N/A
2.39
1.25
N/A
1.28
2.22
1.98
1.83
N/A
Semi Variance
N/A
3.88
1.15
N/A
1.21
3.87
2.87
1.96
N/A

GeneReach Biotechnology Competition Performance Charts

Five steps to successful analysis of GeneReach Biotechnology Competition

GeneReach Biotechnology's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by GeneReach Biotechnology in relation to its competition. GeneReach Biotechnology's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of GeneReach Biotechnology in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact GeneReach Biotechnology's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to GeneReach Biotechnology, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your GeneReach Biotechnology position

In addition to having GeneReach Biotechnology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Target Risk ETFs Thematic Idea Now

Target Risk ETFs
Target Risk ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Target Risk ETFs theme has 32 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Target Risk ETFs Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for GeneReach Stock Analysis

When running GeneReach Biotechnology's price analysis, check to measure GeneReach Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneReach Biotechnology is operating at the current time. Most of GeneReach Biotechnology's value examination focuses on studying past and present price action to predict the probability of GeneReach Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneReach Biotechnology's price. Additionally, you may evaluate how the addition of GeneReach Biotechnology to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY